產品編號
1724060
CAS 號
54573-75-0
中文名稱
(1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-二甲基庚-3-烯-2-基)-7a-甲基六氫-1H-茚-4(2H)-亞乙基)-4-亞甲基環己烷-1,3-二醇
MDL 號
MFCD00871065
分子量
412.65
存儲條件
網頁展示純度為入庫指導純度值,各批次間存在一定差異,實際純度以收貨為準
熔點
沸點
閃點
旋光
描述
TPSA
40.46
LogP
6.6118
H_Acceptors
2
H_Donors
2
Rotatable_Bonds
5
[1]. Francesca Tentori, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015 Jan 7;10(1):98-109.
[2]. Frank Gotch, et al. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration. Blood Purif. 2010;29(2):163-76.
[3]. Jason Gee, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun;73(9):970-8.
[4]. Jun H Choi, et al. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J Card Fail. 2011 Dec;17(12):1051-8.
[5]. Neil Kumar, et al. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations. Am J Nephrol. 2009;29(2):71-8.
警示圖
警示詞
Danger
危險申明
H300
警告申明
P264-P270-P330-P405-P501
GHS 編碼
GHS06
危險類別
6.1
UN 編碼
2811
包裝等級
Ⅲ
現貨供應
專業護航
售后無憂
品質保障
無需湊單